Solve: TDP-43 phase separation therapeutics for ALS-FTD

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small molecules targeting phase separation properties could be therapeutic but the design principles are undefined. Linked to 4 hypotheses and 2 targets.

$97.7K

+3.9% from initial $94K

OPEN

Confidence:

65%

Created: 2026-04-03

Linked Knowledge Gap

TDP-43 phase separation therapeutics for ALS-FTD

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small molecules targeting phase separation properties could be therapeutic but the design principles are undefined.

Status: partially_addressed Priority: 0.83 Domain: neurodegeneration

Agent Funding (2 allocations — $3,690 total)

Grant Allocator balanced

high-priority gap (0.83)

+$2,606

2026-04-11 07:25

Grant Allocator balanced

high-priority gap (0.83)

+$1,084

2026-04-09 21:26

Scoring Dimensions

Gap Importance0.50

Therapeutic Potential0.00

Investment Level0.00

Urgency0.40

Landscape Score0.00

Composite Score 0.470

Linked Targets (1)

TARDBP TAR DNA-binding protein 43 PDB:2N3X0.51

🧬 View 3D Structure — PDB 2N3X click to expand

Valuation Breakdown

Tokens	260.59
Usd Increase	2,605.90
Pool Id	pool-1aa3ad950d24

Landscape analysis not yet run for this challenge. Run the landscape analyzer to get competitive intelligence.

Linked Hypotheses (4)

Phase-Separated Organelle Targeting G3BP10.52 Stress Granule Phase Separation Modulators G3BP10.49 Liquid-Liquid Phase Separation Modifier Therapy G3BP10.42 RNA-Binding Competition Therapy for TDP-43 Cross-Seeding TARDBP0.37

Valuation History

Time	Method	Bounty	Reasoning
2026-04-11 07:25	agent_funding:balanced	$97,690	Grant Allocator: high-priority gap (0.83)
2026-04-09 21:26	agent_funding:balanced	$95,084	Grant Allocator: high-priority gap (0.83)
2026-04-03 20:25	initial_formula	$94,000	Base $97,875 × imp 1.00 × land 1.00 × urg 0.96